Literature DB >> 32283157

Imported COVID-19 cases pose new challenges for China.

Libin Chen1, Juncheng Cai1, Qiuyan Lin1, Bin Xiang2, Tao Ren3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32283157      PMCID: PMC7151481          DOI: 10.1016/j.jinf.2020.03.048

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


× No keyword cloud information.
Dear editor, Recently, a letter in your journal predicted the trend of the spread of the novel coronavirus disease 2019 (COVID-19) in China, an illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), , would end after March 20, 2020. Currently, the COVID-19 has spread around the globe, with the center of the epidemic shifting from China to Europe and the United States. As of March 24, 2020, a total of 372,757 cases have been confirmed worldwide, with a death toll of 16,231 (WHO, Coronavirus disease 2019 Situation Report 64, March 24, 2020). Italy, in particular, had thus far diagnosed 63,927 patients, 6077 of whom had lost their lives. That translates to a mortality rate of 9.51%, which is more than twice as high as that of China's 4.02% (3283/81,747). The greater share of elderly patients with confirmed COVID-19 infection in Italy along with the population's significantly higher median age may partly explain the differences in cases and case-fatality rates between the two nations. Countries such as the United States (42,164 cases), Spain (33,089 cases), Germany (29,212 cases), and France (19,615 cases) have seen an explosive increase in confirmed cases, with the rate of growth showing no hint of slowing down. For China—the initial epicenter of the outbreak—two stages of the epidemic have passed (Fig. 1 A). The first stage is the outbreak period (December 31, 2019 to February 29, 2020), which entailed the period from the first detection of cases to the peak of the epidemic which saw a rapid increase in the number of confirmed cases, and to the time when the growth rate slowed down to less than 200 new confirmed cases per day. In the second stage, which lasted from March 1, 2020 to March 21, 2020, the number of existing cases in most Chinese provinces was reduced to less than 10, respectively, whilst the number of newly confirmed cases in Wuhan, Hubei province, the worst-hit city, was slowly approaching zero. It was during this stage—more specifically on the March 4—that foreign imported cases to appear. During these two stages, the Chinese government, its populous, and its medical professionals had managed to stabilized the deadly epidemic with great deliberation and sacrifices. Currently, however, the situation in China has entered its third stage—recontamination through close contact with foreign infection, as demonstrated by the emergence of second-generation case originated from imported cases first reported in Guangzhou, Guangdong province on March 22, 2020 (Fig. 1B). As of March 24, 2020, there were 427 imported cases and 3 second-generation cases originated from imported cases, one each in Beijing, Shanghai and Guangzhou (National Health Commission of the People's Republic of China). It shows that China needs to pay more attention to the control of imported cases and reflect on the measures previously taken against imported cases.
Fig. 1

Three stages of China's COVID-19 epidemic (updated on March 24, 2020). (A) The first and second stages of China's COVID-19 epidemic. (B) The third stage of China's COVID-19 epidemic. Data for all cases are from World Health Organization (https://www.who.int/emergencies/diseases/novel-coronavirus-2019) and National Health Commission of the People's Republic of China (http://www.nhc.gov.cn).

Three stages of China's COVID-19 epidemic (updated on March 24, 2020). (A) The first and second stages of China's COVID-19 epidemic. (B) The third stage of China's COVID-19 epidemic. Data for all cases are from World Health Organization (https://www.who.int/emergencies/diseases/novel-coronavirus-2019) and National Health Commission of the People's Republic of China (http://www.nhc.gov.cn). Due to the outbreak of COVID-19 in Europe and America, many overseas Chinese or ethnic Chinese had chosen to return to China where the epidemic had remained under control, many of whom were themselves COVID-19 patients without realizing that they had been infected. As a result, imported cases from outside of China appeared in early March and began to increase sharply in mid-March (Fig. 1B). China is now facing increasing pressure in the face of import cases from overseas, especially in cities that a are international travel hubs such as Beijing, Shanghai and Guangzhou. On the onset of this surge in the number of overseas patients, the operational capacity of airports with high volume of international flights was not capable of efficient screening for every arrival, resulting in a large number of passenger flow jams in the airport lobby, and subsequently causing high risk of infection. Therefore, the conundrum regarding the control over overseas imported cases as well as the prevention of a second epidemic outbreak that is fast approaching is a problem that China needs to pay special attention to, especially after the first second-generation case imported from abroad had appeared. It shows that the current prevention and control measures have yet proven to be consummate. As the global epidemic continues in the outbreak period, more and more overseas Chinese citizens or ethnic Chinese, even non-Chinese, will choose to come to China to escape from the epidemic. The government has shortened the processing time for immigration procedures and required all arrivals from other countries to be quarantined. However, the Chinese government needs to ensure that every overseas arrival would have passed a quarantine period of at least 14 days, and tested negative to COVID-19 before they can conduct social activities in the country, and such measures are not easy to implement. China has managed to control the outbreak of the domestic epidemic, but there are still new issues waiting for them to deal with. In addition, China's outstanding performance in the first stage of the epidemic has provided the world with valuable insights and earned two months of breathing room for the world to respond the novel virus. However, due to the lack of attention and the spread of misinformation regarding COVID-19 in many countries, the disease has seriously threatened the whole world, bringing China's epidemic to the third stage. Therefore, based on the One Health model, the outbreak of COVID-19 should concern all humankind, for no country can survive alone. The real victory over COVID-19 will require concerted efforts from around the globe.

Declaration of Competing Interest

None.
  8 in total

1.  Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy.

Authors:  Graziano Onder; Giovanni Rezza; Silvio Brusaferro
Journal:  JAMA       Date:  2020-05-12       Impact factor: 56.272

2.  Emergence of a novel coronavirus causing respiratory illness from Wuhan, China.

Authors:  Julian W Tang; Paul A Tambyah; David S C Hui
Journal:  J Infect       Date:  2020-01-28       Impact factor: 6.072

Review 3.  COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives.

Authors:  Jiumeng Sun; Wan-Ting He; Lifang Wang; Alexander Lai; Xiang Ji; Xiaofeng Zhai; Gairu Li; Marc A Suchard; Jin Tian; Jiyong Zhou; Michael Veit; Shuo Su
Journal:  Trends Mol Med       Date:  2020-03-21       Impact factor: 11.951

4.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

5.  Trend and forecasting of the COVID-19 outbreak in China.

Authors:  Qiang Li; Wei Feng; Ying-Hui Quan
Journal:  J Infect       Date:  2020-02-27       Impact factor: 6.072

6.  Chinese medical personnel against the 2019-nCoV.

Authors:  Zhan-Hui Feng; Yong-Ran Cheng; Juan Chen; Lan Ye; Meng-Yun Zhou; Ming-Wei Wang
Journal:  J Infect       Date:  2020-02-21       Impact factor: 6.072

Review 7.  COVID-19 and Italy: what next?

Authors:  Andrea Remuzzi; Giuseppe Remuzzi
Journal:  Lancet       Date:  2020-03-13       Impact factor: 79.321

8.  Mental health care for international Chinese students affected by the COVID-19 outbreak.

Authors:  Yusen Zhai; Xue Du
Journal:  Lancet Psychiatry       Date:  2020-04       Impact factor: 27.083

  8 in total
  9 in total

Review 1.  Lessons from the coronavirus disease 2019 (COVID-19) pandemic response in China, Italy, and the U.S.: a guide for Africa and low- and middle-income countries.

Authors:  Yanjie Zhang; Isaac Iyinoluwa Olufadewa; Miracle Ayomikun Adesina; Marlene Davis Ekpo; Seyi John Akinloye; Temiloluwa Ololade Iyanda; Pamela Nwachukwu; Lalit Dzifa Kodzo
Journal:  Glob Health J       Date:  2021-02-09

2.  The chilly climate may increase the chance of infecting COVID-19.

Authors:  Gen Li; Jiawei Niu; Xuelei Fan; Tianbao Chen; Dongsheng He
Journal:  J Infect       Date:  2021-02-08       Impact factor: 6.072

3.  The Coupled Impact of Emergency Responses and Population Flows on the COVID-19 Pandemic in China.

Authors:  Changxiu Cheng; Tianyuan Zhang; Changqing Song; Shi Shen; Yifan Jiang; Xiangxue Zhang
Journal:  Geohealth       Date:  2020-12-14

4.  Prevention of SARS-CoV-2 transmission from international arrivals: Xiaotangshan Designated Hospital, China.

Authors:  Zujin Luo; Yi Zhang; Yue Zheng; C Raina MacIntyre; Ying Liang; Quanyi Wang; Yingmin Ma
Journal:  Bull World Health Organ       Date:  2021-03-02       Impact factor: 9.408

5.  Clinical features of 375 COVID-19 cases imported from Russia through the Suifenhe port and countermeasures.

Authors:  Kai Kang; Yi Yang; Xiangdong Guan; Yan Kang; Mingyan Zhao; Jianbo Yu; Xiqiu Zeng; Fengjie Xie; Guolin Chen; Kaijiang Yu
Journal:  PLoS One       Date:  2021-12-16       Impact factor: 3.240

6.  Vaccination as an alternative to non-drug interventions to prevent local resurgence of COVID-19.

Authors:  Jinhua Pan; Wenlong Zhu; Jie Tian; Zhixi Liu; Ao Xu; Ye Yao; Weibing Wang
Journal:  Infect Dis Poverty       Date:  2022-03-26       Impact factor: 4.520

7.  A switching dynamic model based on phased COVID-19 data in Chongqing and its evaluation.

Authors:  Jiang Long; Chenxi Dai; Shanshan Kuang; Han Zhao; Dan Liu; Qing Luo; Kaifa Wang
Journal:  Infect Genet Evol       Date:  2022-03-14       Impact factor: 4.393

8.  Characterization of eight novel full-length genomes of SARS-CoV-2 among imported COVID-19 cases from abroad in Yunnan, China.

Authors:  Yuanyuan Jia; Cuixian Yang; Mi Zhang; Xianyao Yang; Jianjian Li; Jiafa Liu; Ying Liu; XinPing Yang; Yue Feng; Xingqi Dong; Xueshan Xia
Journal:  J Infect       Date:  2020-05-15       Impact factor: 6.072

9.  SARS-Cov-2 trajectory predictions and scenario simulations from a global perspective: a modelling study.

Authors:  Tianan Yang; Yexin Liu; Wenhao Deng; Weigang Zhao; Jianwei Deng
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.